[Progress and prospects of finerenone in the treatment of type 2 diabetes mellitus related chronic kidney disease].

Abstract

The number of patients with type 2 diabetes mellitus (T2DM)-related chronic kidney disease (CKD) is substantial, and the disease burden is severe. Despite current treatment options, even with standard therapy, patients still face a high risk of kidney disease progression and cardiovascular events. Finerenone, a novel, highly selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA), can directly and effectively block kidney and cardiovascular damage caused by excessive activation of mineralocorticoid receptors, while maintaining good safety. This article provides a review of the mechanism of action, clinical application value, guideline recommendations, and future prospects of finerenone.